Core Viewpoint - Femasys Inc. has granted stock options to two new non-executive employees as part of their employment inducement strategy, reflecting the company's commitment to expanding its workforce and enhancing its innovative capabilities in the biomedical sector [1][2]. Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally through a broad, patent-protected portfolio of therapeutic and diagnostic products [3]. - The company is actively commercializing its lead product innovations in the U.S. and key international markets, with a focus on enhancing fertility treatment options and permanent birth control solutions [3]. Product Innovations - Femasys' fertility portfolio includes: - FemaSeed Intratubal Insemination (ITI), which has demonstrated more than double the pregnancy rates of traditional IUI with a comparable safety profile [3]. - FemSperm, a sperm preparation and analysis product line [3]. - FemVue, a companion diagnostic for fallopian tube assessment [3]. - FemBloc is the first and only non-surgical, in-office alternative to surgical sterilization, receiving full regulatory approval in Europe, the UK, and New Zealand in 2025 [4]. - The FemChec diagnostic product provides an ultrasound-based test to confirm procedural success, with initial clinical trials showing compelling effectiveness and high satisfaction rates [4]. Stock Options and Employment Strategy - Femasys granted options to purchase 185,000 shares at exercise prices of $0.50 and $0.57, equal to the closing stock price on the employment date [2]. - The stock options will vest 25% on the first anniversary of employment, with the remaining shares vesting 25% each year over the next three years, contingent on continued employment [2].

Core Viewpoint - Femasys Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share, now having until July 13, 2026, to meet this requirement [1][2]. Company Compliance Status - The extension does not affect the continued listing status of Femasys' common stock on Nasdaq, and compliance will be confirmed if the stock price remains at or above $1.00 for ten consecutive business days [2]. - Femasys is committed to regaining compliance and plans to monitor its share price closely, taking necessary actions within the extension period [3]. Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of therapeutic and diagnostic products [4]. - The company's fertility portfolio includes FemaSeed, which is over twice as effective as traditional IUI, and FemVue, a diagnostic tool for fallopian tube assessment [4]. - FemBloc, a non-surgical permanent birth control method, received regulatory approval in Europe, the UK, and New Zealand in 2025, and is being commercialized through strategic partnerships [5].